CO6362015A2 - Derivados de acido 1-amino-2ciclobutiletilboronico - Google Patents
Derivados de acido 1-amino-2ciclobutiletilboronicoInfo
- Publication number
- CO6362015A2 CO6362015A2 CO11051428A CO11051428A CO6362015A2 CO 6362015 A2 CO6362015 A2 CO 6362015A2 CO 11051428 A CO11051428 A CO 11051428A CO 11051428 A CO11051428 A CO 11051428A CO 6362015 A2 CO6362015 A2 CO 6362015A2
- Authority
- CO
- Colombia
- Prior art keywords
- amino
- acid derivatives
- compounds
- treatment
- pharmaceutical compositions
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- BCNMPHGGRXUKHU-UHFFFAOYSA-N (1-amino-2-cyclobutylethyl)boronic acid Chemical class OB(O)C(N)CC1CCC1 BCNMPHGGRXUKHU-UHFFFAOYSA-N 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
La invención se relaciona con derivados de ácido 1-amino-2-ciclobutiletilborónico útiles como inhibidores de proteasoma, y a composiciones farmacéuticas que comprenden los compuestos de la invención para el tratamiento de diferentes enfermedades de proliferación celular.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19461408P | 2008-09-29 | 2008-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6362015A2 true CO6362015A2 (es) | 2012-01-20 |
Family
ID=41426361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11051428A CO6362015A2 (es) | 2008-09-29 | 2011-04-27 | Derivados de acido 1-amino-2ciclobutiletilboronico |
Country Status (25)
Country | Link |
---|---|
US (3) | US8664200B2 (es) |
EP (1) | EP2346882B1 (es) |
JP (3) | JP5736314B2 (es) |
KR (1) | KR101739470B1 (es) |
CN (2) | CN103554143B (es) |
AR (1) | AR075090A1 (es) |
AU (1) | AU2009297113B2 (es) |
BR (1) | BRPI0919447B8 (es) |
CA (1) | CA2739375C (es) |
CL (1) | CL2011000653A1 (es) |
CO (1) | CO6362015A2 (es) |
CR (2) | CR20160475A (es) |
DO (1) | DOP2011000086A (es) |
EA (1) | EA030539B1 (es) |
EC (1) | ECSP11011011A (es) |
IL (1) | IL211983A0 (es) |
MA (1) | MA32729B1 (es) |
MX (1) | MX2011003317A (es) |
MY (1) | MY166653A (es) |
NZ (2) | NZ592497A (es) |
SG (1) | SG194388A1 (es) |
TW (2) | TWI598352B (es) |
UA (1) | UA105503C2 (es) |
WO (1) | WO2010036357A1 (es) |
ZA (1) | ZA201203615B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2623113T3 (pl) | 2005-11-09 | 2018-05-30 | Onyx Therapeutics, Inc. | Związek do hamowania enzymu |
DK2041158T3 (da) | 2006-06-19 | 2013-06-24 | Onyx Therapeutics Inc | Peptid-epoxidketoner til proteasom inhibering |
KR20170125413A (ko) | 2007-10-04 | 2017-11-14 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
CN103450241A (zh) | 2008-06-17 | 2013-12-18 | 米伦纽姆医药公司 | 硼酸酯化合物及其医药组合物 |
WO2010048298A1 (en) | 2008-10-21 | 2010-04-29 | Proteolix, Inc. | Combination therapy with peptide epoxyketones |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
US9359398B2 (en) * | 2010-03-01 | 2016-06-07 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
US8513218B2 (en) | 2010-03-31 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
US20150184246A1 (en) | 2011-11-11 | 2015-07-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
CN104039328B (zh) | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
BR112014015363A2 (pt) | 2011-12-22 | 2017-06-13 | Ares Trading Sa | derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos |
US20160008382A1 (en) | 2012-01-24 | 2016-01-14 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
WO2014011695A2 (en) | 2012-07-09 | 2014-01-16 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
WO2014086664A1 (en) * | 2012-12-03 | 2014-06-12 | F. Hoffmann-La Roche Ag | Substituted triazole boronic acid compounds |
EA201690686A1 (ru) | 2013-10-03 | 2016-08-31 | Милленниум Фармасьютикалз, Инк. | Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита |
US9988421B2 (en) | 2014-01-10 | 2018-06-05 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
UY36132A (es) | 2014-05-20 | 2015-11-30 | Millennium Pharm Inc | Métodos para terapia de cáncer |
EP4180041A1 (en) | 2014-08-07 | 2023-05-17 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
CN107073069B (zh) | 2014-08-18 | 2022-03-08 | 康奈尔大学 | 作为人免疫蛋白酶体的抑制剂的二肽模拟物 |
EP3201207B1 (en) * | 2014-10-01 | 2021-02-24 | Merck Patent GmbH | Boronic acid derivatives |
CA2963186A1 (en) * | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
US10253049B2 (en) * | 2014-10-01 | 2019-04-09 | Merck Patent Gmbh | Boronic acid derivatives |
US10669289B2 (en) * | 2014-10-01 | 2020-06-02 | Merck Patent Gmbh | Boronic acid derivatives |
ES2905008T3 (es) | 2015-10-15 | 2022-04-06 | Univ Cornell | Inhibidores de proteasomas y usos de los mismos |
JP7164521B2 (ja) | 2016-06-21 | 2022-11-01 | オリオン・オフサルモロジー・エルエルシー | 炭素環式プロリンアミド誘導体 |
EP4257191A3 (en) | 2016-06-21 | 2023-11-22 | Orion Ophthalmology LLC | Heterocyclic prolinamide derivatives |
EP3589659A4 (en) | 2017-02-28 | 2021-03-24 | Mayo Foundation for Medical Education and Research | CANCER TREATMENT COMPOUNDS AND METHODS |
US11203613B2 (en) | 2017-10-11 | 2021-12-21 | Cornell University | Peptidomimetic proteasome inhibitors |
US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
MX2021012305A (es) | 2019-04-12 | 2021-11-12 | Riboscience Llc | Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1. |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ203706A (en) | 1982-04-22 | 1986-03-14 | Squibb & Sons Inc | Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment |
US4499082A (en) * | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
EP0315574A3 (de) * | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
US5159060A (en) | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
DE3827340A1 (de) * | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
EP0583536B1 (en) | 1992-08-14 | 1997-03-05 | The Procter & Gamble Company | Liquid detergents containing an alpha-amino boronic acid |
US5935944A (en) | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
US5492900A (en) | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
US6060462A (en) | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5614649A (en) | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
CN1159061C (zh) | 1997-02-15 | 2004-07-28 | 千年药物公司 | 通过nf-kappab的抑制治疗梗塞 |
EP1017398A1 (en) | 1997-09-25 | 2000-07-12 | Proscript, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
KR20010033150A (ko) | 1997-12-16 | 2001-04-25 | 세파론, 인코포레이티드 | 항종양제용 다촉매 프로테아제 억제제 |
US6169076B1 (en) | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
AU5788800A (en) | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
US6846806B2 (en) * | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
JP4162491B2 (ja) | 2001-01-25 | 2008-10-08 | アメリカ合衆国 | ボロン酸化合物製剤 |
CN100415770C (zh) | 2001-05-30 | 2008-09-03 | 诺瓦提斯公司 | 2-{[n-(2-氨基-3-(杂芳基或芳基)丙酰基)-氨基酰基]-氨基}-烷基硼酸衍生物 |
WO2003033507A1 (fr) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant |
US7524883B2 (en) | 2002-01-08 | 2009-04-28 | Eisai R&D Management Co., Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
WO2003105860A1 (en) | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
US20060084592A1 (en) * | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
TW200418791A (en) * | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
PE20050360A1 (es) * | 2003-08-14 | 2005-06-10 | Cephalon Inc | Inhibidores del proteasoma |
GB0405267D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
RS51983B (en) | 2004-03-30 | 2012-02-29 | Millennium Pharmaceuticals Inc. | SYNTHESIS OF ORGANOBORIC ACID AND ORGANOBORIC ACID COMPOUNDS |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
BRPI0612607A2 (pt) | 2005-07-05 | 2010-12-07 | Tufts College | inibidores de alfa proteìna de ativação de fibroblasto |
WO2007089618A2 (en) | 2006-01-27 | 2007-08-09 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
WO2009006473A2 (en) | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
PT2178888E (pt) | 2007-08-06 | 2012-10-04 | Millennium Pharm Inc | Inibidores do proteassoma |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
CN103450241A (zh) | 2008-06-17 | 2013-12-18 | 米伦纽姆医药公司 | 硼酸酯化合物及其医药组合物 |
US8513218B2 (en) | 2010-03-31 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
-
2009
- 2009-09-12 AR ARP090103760A patent/AR075090A1/es not_active Application Discontinuation
- 2009-09-25 EP EP09789372.1A patent/EP2346882B1/en active Active
- 2009-09-25 MX MX2011003317A patent/MX2011003317A/es active IP Right Grant
- 2009-09-25 MY MYPI2011001392A patent/MY166653A/en unknown
- 2009-09-25 KR KR1020117009732A patent/KR101739470B1/ko active IP Right Grant
- 2009-09-25 NZ NZ592497A patent/NZ592497A/xx not_active IP Right Cessation
- 2009-09-25 WO PCT/US2009/005324 patent/WO2010036357A1/en active Application Filing
- 2009-09-25 CN CN201310475757.1A patent/CN103554143B/zh active Active
- 2009-09-25 JP JP2011529021A patent/JP5736314B2/ja active Active
- 2009-09-25 CN CN200980144074XA patent/CN102203103A/zh active Pending
- 2009-09-25 EA EA201170508A patent/EA030539B1/ru not_active IP Right Cessation
- 2009-09-25 UA UAA201105450A patent/UA105503C2/uk unknown
- 2009-09-25 SG SG2013073267A patent/SG194388A1/en unknown
- 2009-09-25 AU AU2009297113A patent/AU2009297113B2/en not_active Ceased
- 2009-09-25 NZ NZ606001A patent/NZ606001A/en not_active IP Right Cessation
- 2009-09-25 CR CR20160475A patent/CR20160475A/es unknown
- 2009-09-25 US US12/586,650 patent/US8664200B2/en active Active
- 2009-09-25 CA CA2739375A patent/CA2739375C/en active Active
- 2009-09-25 BR BRPI0919447A patent/BRPI0919447B8/pt active IP Right Grant
- 2009-09-29 TW TW105105530A patent/TWI598352B/zh not_active IP Right Cessation
- 2009-09-29 TW TW098133005A patent/TW201024313A/zh unknown
-
2011
- 2011-03-25 CL CL2011000653A patent/CL2011000653A1/es unknown
- 2011-03-28 DO DO2011000086A patent/DOP2011000086A/es unknown
- 2011-03-28 IL IL211983A patent/IL211983A0/en unknown
- 2011-04-26 CR CR20110216A patent/CR20110216A/es unknown
- 2011-04-26 MA MA33796A patent/MA32729B1/fr unknown
- 2011-04-27 CO CO11051428A patent/CO6362015A2/es active IP Right Grant
- 2011-04-28 EC EC2011011011A patent/ECSP11011011A/es unknown
-
2012
- 2012-05-17 ZA ZA2012/03615A patent/ZA201203615B/en unknown
-
2014
- 2014-01-13 US US14/153,752 patent/US9771381B2/en active Active
-
2015
- 2015-04-20 JP JP2015085803A patent/JP2015143264A/ja active Pending
-
2016
- 2016-10-11 JP JP2016199804A patent/JP2017025091A/ja active Pending
-
2017
- 2017-08-18 US US15/680,514 patent/US10035811B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6362015A2 (es) | Derivados de acido 1-amino-2ciclobutiletilboronico | |
ECSP11011183A (es) | Compuestos orgánicos | |
ECSP11011184A (es) | Compuestos orgánicos | |
CR20120529A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
DOP2014000062A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
CO6680683A2 (es) | Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias | |
UY35467A (es) | Compuestos orgánicos | |
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
CR20120334A (es) | Derivados de imidazopiridina como inhibidores de jak | |
UY33735A (es) | Compuestos antivirales | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
GT201000023A (es) | Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met. | |
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
CO6670585A2 (es) | Promotores de apotosis n-acilsufonamidas | |
CU20110204A7 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
HN2010001920A (es) | Dihidropirazolonas sustituidas como inhibidores de hif- propil-4-hidroxilasa | |
GT201400090A (es) | 2-tiopirimidinonas | |
ECSP11010992A (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales | |
UA107183C2 (uk) | Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань | |
UY31487A1 (es) | Derivados de pirazol como inhibidores de 5-lo | |
CO6592046A2 (es) | 5-alquinil pirimidas y su uso como inhibidores de quinasa | |
ECSP10010292A (es) | Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |